Novan, Inc. (NASDAQ:NOVN)
Industry: PharmaceuticalsMajor

Novan, Inc., a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Current Quote*
Last: $0.001
Change: 0.000
Book: $64.500
Volume: 6,563

As Of: 04/15 13:00 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol NOVN

  • No BuyIns.Net Alerts Available for NOVN

Graphs for NOVN


3 Month Graph


6 Month Graph


1 Year Graph